Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma Clinical Trial

Official title:

A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00978432
• Other study ID #: Pro00012947
• Status: Active, not recruiting
• Phase: Phase 2
• First received: September 15, 2009
• Last updated: August 3, 2015
• Start date: February 2012
• Est. completion date: June 2018

Study information

• Verified date: August 2015
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is evaluate the response, safety and tolerability in subjects receiving the investigational drugs, RAD001 and LBH589. Subjects in Part 1 will receive one drug for four cycles followed by 4 cycles of the second drug unless they achieve complete remission. Subjects in a complete remission may receive up to 6 cycles of study drug and will not receive the next study drug until there is evidence of disease progression. Subjects in Part 2 will receive both drugs together for at least 2 cycles and up to 13 if tolerated.

Description:

This will be a prospective, non-randomized, un-blinded phase 2 efficacy trial using a mechanistic target of rapamycin (mTOR) inhibitor and a histone deacetylase (HDAC) inhibitor for epigenetic targeted therapies.

Subjects will receive RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be assessed for disease status after 2 cycles and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better les may receive up to 13 cycles. LBH589 was given at 40mg when the study first opened and was changed to 20mg po shortly thereafter. LBH589 is taken on days M/W/F. RAD001 was given at 10mg po daily for Part 1. In Part 2, LBH589 is given at 15mg and RAD001 is given at 7.5mg.

Treatment will be administered on an outpatient basis. Patients will be followed for up to 2 years after completion of therapy or until progression of disease or death.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 75
• Est. completion date: June 2018
• Est. primary completion date: April 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. de novo or transformed Diffuse large B cell non-Hodgkin lymphoma (DLBCL). DLBCL-like lymphomas allowed:

• Epstei-Barr virus (EBV)+ DLBCL in elderly,

• DLBCL with chronic inflammation,

• Primary cutaneous DLBCL, leg type,

• B cell lymphoma unclassifiable - between DLBCL and Burkitt lymphoma,

• B cell lymphoma unclassifiable - between large B cell lymphoma and classical Hodgkin lymphoma,

• Anaplastic lymphoma kinase (ALK)+ large B cell lymphoma,

• T cell histiocyte rich large B cell lymphoma

• Primary mediastinal B cell lymphoma

• Follicular grade 3 B cell lymphoma

2. Refractory or relapsed disease to >/= 1 prior treatment regimen: should include autologous stem cell transplant unless patient refused or ineligible.

3. Age > 18 years old

4. Eastern Cooperative Oncology Group (ECOG) performance status <2.

5. Measurable or evaluable disease by physical exam, radiographs or bone marrow involvement

6. Frozen tumor or paraffin-embedded sample available.

7. 3-4 core fresh/fresh-frozen biopsy specimens available. Leukapheresis may be done for patients with leukocytosis.

8. Laboratory Values per protocol.

Exclusion Criteria:

1. Laboratory Values

• Grade 3 hyperlipidemia (Serum cholesterol >400mg/dl or serum triglycerides >5 x ULN)

• Serum Glucose > 250mg/dl on >/= 2 checks on 2 separate days

• Diabetics accepted if sugars controlled

2. Unlimited prior chemotherapy regimens, however:

• No prior exposure to RAD001 or LBH589 or drugs that target mTOR (sirolimus, temsirolimus, etc) or HDAC (vorinostat)

• No valproic acid during study or 5 days preceding start of first drug

• No chemotherapy, biologics or immunotherapy < 2 weeks before registration (6 weeks if last received bis-chloroethylnitrosourea (BCNU) or mitomycin C). Subjects must be recovered from therapy-related non-hematological toxicities to < grade 1 or baseline if started with > grade 1 toxicity.

• No time limit for radiation prior to registration.

• No radioimmunotherapy < 2 months prior to registration. Subjects must be recovered from therapy-related toxicities to < grade 1 or baseline if started with > grade 1 toxicity.

• No prior allogeneic stem cell transplantation unless allogeneic engraftment is <2%.

• Subjects receiving chronic, systemic treatment with corticosteroids = to >20mg of prednisone per day.

• Subjects receiving replacement for adrenal insufficiency allowed.

• Topical or inhaled corticosteroids allowed.

3. History of other primary malignancy < 3 years ago, except inactive basal, squamous cell carcinoma of the skin or superficial melanoma only requiring excision, prostate cancer with a prostate specific antigen (PSA) stable for >/=3 months, carcinoma in situ of cervix.

4. Major surgery < 4 weeks before or Minor surgery < 2 weeks before registration. Subjects must be recovered from toxicities to < grade 1 or baseline if started with > grade 1 toxicity.

5. Investigational drugs < 4 weeks prior to registration.

6. Impaired Cardiac Function per protocol.

7. Pregnant or breastfeeding females or adults of reproductive potential not using effective birth control

8. Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO) < 40% if tested (per protocol).

9. Impaired lung function: O2 saturation 88% or less at rest on room air by Pulse Oximetry.

10. Immunization with live attenuated vaccines < 1 week of study entry

11. Impaired GI function or GI disease that may alter absorption of RAD001 or LBH589

12. Concurrent severe &/or uncontrolled medical conditions

13. Medications with risk of prolonging QT interval or inducing torsade de pointes or interacting with LBH589 and RAD001 may be used per the protocol.

14. Active bleeding tendency

15. Positive for HIV.

16. Positive for Hepatitis C virus (HCV).

17. History of non-compliance to medical regimens.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diffuse Large B-cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Intervention

Drug:
• RAD001
10 mg/day for Part 1 of the trial
• LBH589
40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
• Doublet (RAD001 and LBH589)
RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Anne Beaven, MD	Novartis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate	Overall Response Rate is the number of participants with a partial and complete response assessed by the Updated Cheson criteria for lymphoma. A complete response is complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy and normalization of those biochemical abnormalities. If a subject has residual lesions on CT scan and the disease was fluorodeoxyglucose (FDG) avid pre-treatment, then that subject will be considered to be in a complete response. Partial response is a greater than or equal to 50% decrease in the sum of the products of the greatest diameters of 6 largest dominant nodes or nodal masses. No increase in size of nodes, liver or spleen and no new sites of disease	From the start of combination therapy until a maximum of 2 years after completion of therapy	No
Primary	Assessment of association between observed response to RAD001 and LBH589 and the response predicted by molecular signatures developed in our pre-clinical model	We will estimate the association of the molecular signature-predicted response to the doublet (CR+PR) with the observed response. All evaluable patients will be used in estimating response. The chi-square test with one-sided alpha of 0.10 will be used to test for the association between predicted and observed responses. Contingency tables will be used to present these associations.	From the start of combination therapy until a maximum of 2 years after completion of therapy	No
Secondary	Summary of Adverse Events (AEs)	Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose). National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) is used to assess severity. Relatedness to study drug is assessed by the investigator.	From the time of first dose of study drug until 4 weeks after participant has stopped study drug	Yes
Secondary	Distribution of change across time of mTOR and HDAC-I inhibition from baseline until after the 1st 2 cycles of study drug in patients who received LBH and RAD.	Serum markers will be measured on the first day of cycle 1 and on the first day of cycle 3. The distribution of change across time in a marker will be summarized.	after 2 cycles of study therapy	No
Secondary	Evaluate the association of observed response to the doublet with the response predicted by molecular signatures for activated B cell like (ABC) DLBCL and for Germinal Center B cell like (GCB) DLBCL.	Response rates seen in subjects with activated B cell like DLBCL and for Germinal center B cell like DLBCL will be reported and assessed to see if GCB is associated with improved outcomes compared to ABC in subjects with relapsed disease who have received RAD + LBH. We will estimate the association of the ABC and GCB with the observed response. All evaluable patients will be used in estimating response. The chi-square test with one-sided alpha of 0.10 will be used to test for the association between predicted and observed responses.	up to 13 cycles of therapy	No